Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | AR | P10275 | 4/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | ESR1 | P03372 | 3/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.73 |
| ▸ | SHBG | P04278 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norbolethone SCHEMBL16755266 | 1.00 | PGR (0.73) | PGRLMNAARSLC6A4CYP3A4 | |
| Norbolethone SCHEMBL6716010 | 1.00 | PGR (0.73) | PGRLMNAARSLC6A4CYP3A4 | |
| Norbolethone SCHEMBL7793965 | 1.00 | PGR (0.73) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11859513 | 0.92 | PGR (0.66) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11860944 | 0.92 | PGR (0.69) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11862165 | 0.90 | LMNA (0.64) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11861924 | 0.89 | PGR (0.66) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11857196 | 0.89 | PGR (0.66) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11646807 | 0.89 | PGR (0.66) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11858609 | 0.88 | PGR (0.64) | PGRLMNAARSLC6A4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | claimed |
| EP-2320912-B1 | TREATMENT OF RETINAL DEGENERATION | UNIV COLLEGE CORK NAT UNIV IE (IE) | 2015-01-14 | — | — | EP | claimed |
| US-8518890-B2 | Luteinizing hormone-releasing hormone receptor agonist leuprorelin, or antagonist with androgen receptor agonist for prophylaxis, treatment of prostate cancer; dehydroepiandrosterone, testosterone, dihydrotestosterone; non-steroidal androgen receptor agonist; estradiol, estrone, estriol, stilbestrol | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-27 | — | — | US | claimed |
| CN-101883556-B | Transdermal delivery system for hormones and steroids | ACRUX DDS PTY LTD | 2013-05-29 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120196837-A1 | METHOD OF TREATING FRAILTY | ETROEN B.V. (NL) | 2012-08-02 | — | — | US | claimed |
| US-20030152615-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| US-20030152614-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| WO-2002102390-A1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMACEUTICALS, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-6262115-B1 | ADMITTING ORALLY INTO THE PATIENT A DOSAGE FORM OF OXYBUTYNIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALT, THAT IS ADMINISTERED ONCE-A-DAY AS SUSTAINED-RELEASE FORM FOR MANAGEMENT OF INCONTINENCE | ALZA COPORATION | 2001-07-17 | — | — | US | claimed |
| US-20010005728-A1 | Method for the management of incontinence | ALZA CORPORATION | 2001-06-28 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0500793-B1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORP (US) | 1993-11-03 | — | — | EP | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |